

SYNERGY PHARMACEUTICALS, INC.

Form 8-K

October 18, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 18, 2010**

---

**Synergy Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Florida**  
(State or other jurisdiction  
of incorporation)

**333-131722**  
(Commission File Number)

**20-3823853**  
(IRS Employer  
Identification No.)

**420 Lexington Avenue, Suite 1609**

**New York, NY 10170**

Edgar Filing: SYNERGY PHARMACEUTICALS, INC. - Form 8-K

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(212) 297-0020**

---

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On October 18, 2010, Synergy Pharmaceuticals, Inc. (the Company) presented clinical results from a Phase IIa clinical trial of plecanatide (SP-304) in patients with chronic constipation at the American College of Gastroenterology Annual Scientific Meeting. The Company's presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibit is filed with this report:

Exhibit No.	Description
99.1	Synergy Pharmaceuticals, Inc. Company Presentation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SYNERGY PHARMACEUTICALS, INC.**

Dated: October 18, 2010

/s/ Gary S. Jacob  
Gary S. Jacob  
President and Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Synergy Pharmaceuticals, Inc. Company Presentation.

4

---